Wesana Health Reports Q3 2021 Financial Results

NEXT STORY
Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
PREV STORY
Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer

author_avatar
NASDAQ Market News

Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan

Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to ...

author_avatar
NASDAQ Market News

Novan Announces Inclusion in Russell Microcap® Index

author_avatar
NASDAQ Market News